Background: The Multimodal Treatment Study (MTA) began as a 14-month randomized clinical trial of behavioral and pharmacological treatments of 579 children (7-10 years of age) diagnosed with attention-deficit/hyperactivity disorder (ADHD)-combined type. It transitioned into an observational long-term follow-up of 515 cases consented for continuation and 289 classmates (258 without ADHD) added as a local normative comparison group (LNCG), with assessments 2-16 years after baseline.
Methods: Primary (symptom severity) and secondary (adult height) outcomes in adulthood were specified. Treatment was monitored to age 18, and naturalistic subgroups were formed based on three patterns of long-term use of stimulant medication (Consistent, Inconsistent, and Negligible). For the follow-up, hypothesis-generating analyses were performed on outcomes in early adulthood (at 25 years of age). Planned comparisons were used to estimate ADHD-LNCG differences reflecting persistence of symptoms and naturalistic subgroup differences reflecting benefit (symptom reduction) and cost (height suppression) associated with extended use of medication.
Results: For ratings of symptom severity, the ADHD-LNCG comparison was statistically significant for the parent/self-report average (0.51 ± 0.04, p < .0001, d = 1.11), documenting symptom persistence, and for the parent/self-report difference (0.21 ± 0.04, p < .0001, d = .60), documenting source discrepancy, but the comparisons of naturalistic subgroups reflecting medication effects were not significant. For adult height, the ADHD group was 1.29 ± 0.55 cm shorter than the LNCG (p < .01, d = .21), and the comparisons of the naturalistic subgroups were significant: the treated group with the Consistent or Inconsistent pattern was 2.55 ± 0.73 cm shorter than the subgroup with the Negligible pattern (p < .0005, d = .42), and within the treated group, the subgroup with the Consistent pattern was 2.36 ± 1.13 cm shorter than the subgroup with the Inconsistent pattern (p < .04, d = .38).
Conclusions: In the MTA follow-up into adulthood, the ADHD group showed symptom persistence compared to local norms from the LNCG. Within naturalistic subgroups of ADHD cases, extended use of medication was associated with suppression of adult height but not with reduction of symptom severity.
Keywords: Attention-deficit/hyperactivity disorder; follow-up studies; growth; longitudinal studies; medication effects; treatment trials.
© 2017 Association for Child and Adolescent Mental Health.
Conflict of interest statement
Conflict of interest statement: See Acknowledgements for disclosures.
Functional Adult Outcomes 16 Years After Childhood Diagnosis of Attention-Deficit/Hyperactivity Disorder: MTA Results.J Am Acad Child Adolesc Psychiatry. 2016 Nov;55(11):945-952.e2. doi: 10.1016/j.jaac.2016.07.774. Epub 2016 Sep 2. J Am Acad Child Adolesc Psychiatry. 2016. PMID: 27806862 Free PMC article.
Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder.J Am Acad Child Adolesc Psychiatry. 2019 Aug 15:S0890-8567(19)31443-1. doi: 10.1016/j.jaac.2019.06.019. Online ahead of print. J Am Acad Child Adolesc Psychiatry. 2019. PMID: 31421233
National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.Pediatrics. 2004 Apr;113(4):762-9. doi: 10.1542/peds.113.4.762. Pediatrics. 2004. PMID: 15060225 Clinical Trial.
Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults.Cochrane Database Syst Rev. 2018 Mar 23;3(3):CD010840. doi: 10.1002/14651858.CD010840.pub2. Cochrane Database Syst Rev. 2018. PMID: 29566425 Free PMC article. Review.
Methylphenidate for children and adolescents with autism spectrum disorder.Cochrane Database Syst Rev. 2017 Nov 21;11(11):CD011144. doi: 10.1002/14651858.CD011144.pub2. Cochrane Database Syst Rev. 2017. PMID: 29159857 Free PMC article. Review.
Cited by 32 articles
Executive and non-executive functions in low birthweight/preterm adolescents with differing temporal patterns of inattention.PLoS One. 2020 Apr 24;15(4):e0231648. doi: 10.1371/journal.pone.0231648. eCollection 2020. PLoS One. 2020. PMID: 32330149 Free PMC article.
Micronutrients and Diets in the Treatment of Attention-Deficit/Hyperactivity Disorder: Chances and Pitfalls.Front Psychiatry. 2020 Feb 26;11:102. doi: 10.3389/fpsyt.2020.00102. eCollection 2020. Front Psychiatry. 2020. PMID: 32174856 Free PMC article. No abstract available.
Quantifying the Protective Effects of Stimulants on Functional Outcomes in Attention-Deficit/Hyperactivity Disorder: A Focus on Number Needed to Treat Statistic and Sex Effects.J Adolesc Health. 2019 Dec;65(6):784-789. doi: 10.1016/j.jadohealth.2019.05.015. Epub 2019 Jul 23. J Adolesc Health. 2019. PMID: 31350122
Depression and ADHD-Related Risk for Substance Use in Adolescence and Early Adulthood: Concurrent and Prospective Associations in the MTA.J Abnorm Child Psychol. 2019 Dec;47(12):1903-1916. doi: 10.1007/s10802-019-00573-y. J Abnorm Child Psychol. 2019. PMID: 31273568
Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.Biol Psychiatry. 2019 Sep 1;86(5):335-343. doi: 10.1016/j.biopsych.2019.04.009. Epub 2019 Apr 17. Biol Psychiatry. 2019. PMID: 31155139 Review.
- U01 MH050467/MH/NIMH NIH HHS/United States
- N01MH12007/MH/NIMH NIH HHS/United States
- N01 MH012008/MH/NIMH NIH HHS/United States
- N01MH12010/MH/NIMH NIH HHS/United States
- N01MH12008/MH/NIMH NIH HHS/United States
- U01 MH050461/MH/NIMH NIH HHS/United States
- HHSN271200800004C/DA/NIDA NIH HHS/United States
- U01 MH050440/MH/NIMH NIH HHS/United States
- N01 DA085548/DA/NIDA NIH HHS/United States
- N01 MH012012/MH/NIMH NIH HHS/United States
- N01MH12011/MH/NIMH NIH HHS/United States
- HHSN271200800003C/DA/NIDA NIH HHS/United States
- N01 DA085549/DA/NIDA NIH HHS/United States
- N01 MH012010/MH/NIMH NIH HHS/United States
- HHSN271200800009C/DA/NIDA NIH HHS/United States
- HHSN271200800005C/DA/NIDA NIH HHS/United States
- N01MH12009/MH/NIMH NIH HHS/United States
- U54 HD090257/HD/NICHD NIH HHS/United States
- HHSN271200800006C/DA/NIDA NIH HHS/United States
- N01 DA085553/DA/NIDA NIH HHS/United States
- N01 MH012011/MH/NIMH NIH HHS/United States
- K23 DA032577/DA/NIDA NIH HHS/United States
- N01 MH012004/MH/NIMH NIH HHS/United States
- N01 DA085554/DA/NIDA NIH HHS/United States
- N01 MH012009/MH/NIMH NIH HHS/United States
- U01 MH050453/MH/NIMH NIH HHS/United States
- N01 MH012007/MH/NIMH NIH HHS/United States
- N01 DA085551/DA/NIDA NIH HHS/United States
- HHSN271200800008C/DA/NIDA NIH HHS/United States
- N01MH12012/MH/NIMH NIH HHS/United States
- N01MH12004/MH/NIMH NIH HHS/United States
- N01 DA085550/DA/NIDA NIH HHS/United States
- HHSN271200800007C/DA/NIDA NIH HHS/United States
- R01 DA039881/DA/NIDA NIH HHS/United States